Viewing nowCombinationEsoglitazone Tablet 25/5 mg
Empagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.

MFDS item code 201701587 · Approved 2017.03.31 · Insurance code 653501600
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. The combination of empagliflozin and linagliptin effectively manages blood sugar levels, thereby aiding in diabetes management by maintaining stable blood sugar levels.
The recommended starting dose of this drug is empagliflozin 10 mg/linagliptin 5 mg once daily. If additional glycemic control is needed in patients who tolerate empagliflozin 10 mg/linagliptin 5 mg, the dose of this drug may be increased to 25/5 mg once daily. Patients switching from combination therapy with empagliflozin and linagliptin to this drug should receive their previous doses. This drug may be taken with or without food. Swallow the tablet whole. If a dose of this drug is missed, take it as soon as remembered. However, if the time for the next dose is within 12 hours, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose on the same day. Patients with renal impairment This drug is not recommended for improving glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dosage adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. Older adults No dosage adjustment based on age is necessary. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication contains two active ingredients, empagliflozin and linagliptin, which are diabetes treatments that help control blood sugar levels. This medication should not be used in certain patients. For example, those allergic to its components, those with type 1 diabetes, diabetic ketoacidosis, and patients on dialysis should not take this medication. Patients with impaired kidney function should have their kidney function regularly checked before taking this medication, and caution is also warranted if taking other medications that may affect kidney function. Patients with heart failure or a history of pancreatitis should use this medication cautiously, and if acute pancreatitis symptoms, such as severe abdominal pain, occur, they should stop taking it immediately. Additionally, a condition called bullous pemphigoid may occur, presenting as blisters on the skin, so it is important to consult a physician if skin abnormalities develop. When taking this medication, side effects like urinary tract infections, genital infections, hypoglycemia, dehydration, and low blood pressure may occur, so it is crucial to inform healthcare professionals immediately if symptoms arise. Particularly, when taken with other diabetes medications such as insulin or sulfonylureas, the risk of hypoglycemia may increase, which may require dosage adjustments. This medication is not recommended for use in pregnant or breastfeeding women, and it is best not to use it in children under 18 years of age as safety and efficacy have not been established. In case of overdose, treatment such as gastrointestinal decontamination may be necessary, so it is essential to adhere to the prescribed dosage. Lastly, keep this medication out of reach of children and store it in its original packaging.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will help preserve the medication's efficacy.
Light pink triangular film-coated tablet with a flat surface and sharp edges.
30 tablets/PTP [(10 tablets/PTP * 3)], 10 tablets/PTP [(10 tablets/PTP * 1)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Dongkoo Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
Empagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Empagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.